Chapters

Transcript

Video

In light of PRIMO and collateral studies about the safety, tolerability, efficacy, dosing, and combinatorial studies based on duvelisib, can you discuss the TERZO trial design and what we expect to learn in R/R PTCL-TFH?


Created by

CMEducation Resources iQ&A PTCL Hematology-Oncology Intelligence Zone

Presenter

Steven Horwitz, MD

Steven Horwitz, MD

Associate Attending, Department of Medicine Medical Oncologist, Lymphoma Specialist and Cellular TherapistMemorial Sloan Kettering Cancer Center (MSKCC)New York, New York